Antibody persistence following meningococcal C conjugate vaccination in children and adolescents infected with human immunodeficiency virus
Abstract Objective: HIV-infected individuals (HIVI) are threatened by meningococcal infection and presented lower response to vaccines. Data are scarce on long-term persistence of human serum bactericidal antibody (hSBA) after a meningococcal C conjugate (MCC) vaccine in HIVI youth; the authors aim...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
|
| Series: | Jornal de Pediatria |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572017000500532&lng=en&tlng=en |
| _version_ | 1811308559674114048 |
|---|---|
| author | Ana Cristina Cisne Frota Lee H. Harrison Bianca Ferreira Daniela Menna-Barreto Raquel Bernardo Nana de Castro Giselle Pereira da Silva Ricardo Hugo de Oliveira Thalita F. Abreu Lucimar G. Milagres Cristina B. Hofer |
| author_facet | Ana Cristina Cisne Frota Lee H. Harrison Bianca Ferreira Daniela Menna-Barreto Raquel Bernardo Nana de Castro Giselle Pereira da Silva Ricardo Hugo de Oliveira Thalita F. Abreu Lucimar G. Milagres Cristina B. Hofer |
| author_sort | Ana Cristina Cisne Frota |
| collection | DOAJ |
| description | Abstract Objective: HIV-infected individuals (HIVI) are threatened by meningococcal infection and presented lower response to vaccines. Data are scarce on long-term persistence of human serum bactericidal antibody (hSBA) after a meningococcal C conjugate (MCC) vaccine in HIVI youth; the authors aimed to describe this persistence in HIVI. Methods: HIVI and HIV uninfected individuals (HIVU), aged 2–18 years, CD4 >15% were recruited. Seroprotection (hSBA ≥1:4) at baseline and at 12–18 months after immunization was evaluated and the association of the different factors with the long-term persistence was calculated using logistic regression. Results: A total of 145 HIVI, 50 HIVU were recruited and immunized, and their median age was 11 years (median age in HIVI group was 12 years, and 10 years in HIVU group, p-value = 0.02). 85 HIVI (44%) had undetectable viral load (UVL). Seroprotection rate was 27.2%: 24.1% in HIVI and 36% in HIVU 12–18 months after immunization (p = 0.14). Baseline immunity (odds ratio [OR] = 70.70, 95% CI: 65.2–766.6); UVL at entry (OR: 2.87, 95% CI: 0.96–8.62) and lower family income (OR: 0.09, 95% CI: 0.01–0.69) were associated with seroprotection among HIVI. Conclusion: Seroprotection at 12–18 months after single dose of MCC was low for both groups, and higher among individuals who presented baseline immunity. Among HIVI, vaccine should be administered after UVL is achieved. |
| first_indexed | 2024-04-13T09:25:19Z |
| format | Article |
| id | doaj.art-431a4d4c019643dab711f766e4170a40 |
| institution | Directory Open Access Journal |
| issn | 1678-4782 |
| language | English |
| last_indexed | 2024-04-13T09:25:19Z |
| publisher | Elsevier |
| record_format | Article |
| series | Jornal de Pediatria |
| spelling | doaj.art-431a4d4c019643dab711f766e4170a402022-12-22T02:52:27ZengElsevierJornal de Pediatria1678-478293553253710.1016/j.jped.2017.01.003S0021-75572017000500532Antibody persistence following meningococcal C conjugate vaccination in children and adolescents infected with human immunodeficiency virusAna Cristina Cisne FrotaLee H. HarrisonBianca FerreiraDaniela Menna-BarretoRaquel Bernardo Nana de CastroGiselle Pereira da SilvaRicardo Hugo de OliveiraThalita F. AbreuLucimar G. MilagresCristina B. HoferAbstract Objective: HIV-infected individuals (HIVI) are threatened by meningococcal infection and presented lower response to vaccines. Data are scarce on long-term persistence of human serum bactericidal antibody (hSBA) after a meningococcal C conjugate (MCC) vaccine in HIVI youth; the authors aimed to describe this persistence in HIVI. Methods: HIVI and HIV uninfected individuals (HIVU), aged 2–18 years, CD4 >15% were recruited. Seroprotection (hSBA ≥1:4) at baseline and at 12–18 months after immunization was evaluated and the association of the different factors with the long-term persistence was calculated using logistic regression. Results: A total of 145 HIVI, 50 HIVU were recruited and immunized, and their median age was 11 years (median age in HIVI group was 12 years, and 10 years in HIVU group, p-value = 0.02). 85 HIVI (44%) had undetectable viral load (UVL). Seroprotection rate was 27.2%: 24.1% in HIVI and 36% in HIVU 12–18 months after immunization (p = 0.14). Baseline immunity (odds ratio [OR] = 70.70, 95% CI: 65.2–766.6); UVL at entry (OR: 2.87, 95% CI: 0.96–8.62) and lower family income (OR: 0.09, 95% CI: 0.01–0.69) were associated with seroprotection among HIVI. Conclusion: Seroprotection at 12–18 months after single dose of MCC was low for both groups, and higher among individuals who presented baseline immunity. Among HIVI, vaccine should be administered after UVL is achieved.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572017000500532&lng=en&tlng=enVacina meningocócicaImunologiaVacinas conjugadasHIVCriançasBrasil |
| spellingShingle | Ana Cristina Cisne Frota Lee H. Harrison Bianca Ferreira Daniela Menna-Barreto Raquel Bernardo Nana de Castro Giselle Pereira da Silva Ricardo Hugo de Oliveira Thalita F. Abreu Lucimar G. Milagres Cristina B. Hofer Antibody persistence following meningococcal C conjugate vaccination in children and adolescents infected with human immunodeficiency virus Jornal de Pediatria Vacina meningocócica Imunologia Vacinas conjugadas HIV Crianças Brasil |
| title | Antibody persistence following meningococcal C conjugate vaccination in children and adolescents infected with human immunodeficiency virus |
| title_full | Antibody persistence following meningococcal C conjugate vaccination in children and adolescents infected with human immunodeficiency virus |
| title_fullStr | Antibody persistence following meningococcal C conjugate vaccination in children and adolescents infected with human immunodeficiency virus |
| title_full_unstemmed | Antibody persistence following meningococcal C conjugate vaccination in children and adolescents infected with human immunodeficiency virus |
| title_short | Antibody persistence following meningococcal C conjugate vaccination in children and adolescents infected with human immunodeficiency virus |
| title_sort | antibody persistence following meningococcal c conjugate vaccination in children and adolescents infected with human immunodeficiency virus |
| topic | Vacina meningocócica Imunologia Vacinas conjugadas HIV Crianças Brasil |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572017000500532&lng=en&tlng=en |
| work_keys_str_mv | AT anacristinacisnefrota antibodypersistencefollowingmeningococcalcconjugatevaccinationinchildrenandadolescentsinfectedwithhumanimmunodeficiencyvirus AT leehharrison antibodypersistencefollowingmeningococcalcconjugatevaccinationinchildrenandadolescentsinfectedwithhumanimmunodeficiencyvirus AT biancaferreira antibodypersistencefollowingmeningococcalcconjugatevaccinationinchildrenandadolescentsinfectedwithhumanimmunodeficiencyvirus AT danielamennabarreto antibodypersistencefollowingmeningococcalcconjugatevaccinationinchildrenandadolescentsinfectedwithhumanimmunodeficiencyvirus AT raquelbernardonanadecastro antibodypersistencefollowingmeningococcalcconjugatevaccinationinchildrenandadolescentsinfectedwithhumanimmunodeficiencyvirus AT gisellepereiradasilva antibodypersistencefollowingmeningococcalcconjugatevaccinationinchildrenandadolescentsinfectedwithhumanimmunodeficiencyvirus AT ricardohugodeoliveira antibodypersistencefollowingmeningococcalcconjugatevaccinationinchildrenandadolescentsinfectedwithhumanimmunodeficiencyvirus AT thalitafabreu antibodypersistencefollowingmeningococcalcconjugatevaccinationinchildrenandadolescentsinfectedwithhumanimmunodeficiencyvirus AT lucimargmilagres antibodypersistencefollowingmeningococcalcconjugatevaccinationinchildrenandadolescentsinfectedwithhumanimmunodeficiencyvirus AT cristinabhofer antibodypersistencefollowingmeningococcalcconjugatevaccinationinchildrenandadolescentsinfectedwithhumanimmunodeficiencyvirus |